- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
David Newman, GlaxoSmithKline
S
David Newman
Senior Product Director, Tykerb, GlaxoSmithKline
NOTED FOR: Launch of oncology treatment Tykerb
EXCEEDED RESULTS: Treated 5,500 patients
On what motivates him to succeed:
We think we have it tough. But that's nothing compared to fighting breast cancer. These women help us put our work in perspective, and give us a sense of mission to not necessarily sell Tykerb, but instead make sure every patient gets its benefit of efficacy.
David Newman
In a therapeutic area like oncology, you have a chance to make a real difference. That focus is what keeps me motivated day in and day out.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
